• Publications
  • 2019 Methodology for the 2020 Antimicrobial R...
Publication - published on 14 Feb 2019

2019 Methodology for the 2020 Antimicrobial Resistance Benchmark

This is the latest framework for tracking how pharmaceutical companies are responding to antimicrobial resistance (AMR). In 2019, the Access to Medicine Foundation will use it to track the progress of 30 pharmaceutical companies in slowing AMR.

Bacteria and other pathogens are becoming resistant to antimicrobials, making it increasingly difficult to treat infections. A global effort to slow AMR is gathering pace, and the role for pharmaceutical companies is clear: to develop new medicines to replace ones that no longer work, and find new ways to ensure antibiotics are produced and promoted responsibly, i.e., through ‘stewardship’.

To evaluate progress toward this goal, the 2020 Benchmark will use a framework of 19 indicators organised into three Research Areas: Research & Development, Responsible Manufacturing and Appropriate Access & Stewardship. Access metrics will capture companies’ activities in 102 mainly low- and middle-income countries where people have a particularly acute need for greater access to medicine.

The companies in scope include some of the largest in the global antibacterials market as well as companies with important clinical-stage pipelines. Three types of companies are in scope: large R&D-based pharmaceutical companies, generic medicine manufacturers and clinical-stage biopharmaceutical companies. To track key companies with important antibacterial and antifungal assets, and considering the most recent market intelligence data, eight companies are newly in scope for the 2020 AMR Benchmark.

The 2020 AMR Benchmark will focus on how companies are limiting resistance in bacteria and fungi, particularly priority pathogens.   

The Foundation will now begin the process of data collection, verification, scoring and analysis, before publishing the next Antimicrobial Resistance Benchmark early in 2020.

After this report was initially published, the company scope has been further revised and one section of the report (pages 20-22) has been corrected to show that Amplyx is now in scope of the 2020 AMR Benchmark. The initial version showed that F2G was also in scope of the 2020 AMR Benchmark, but this is no longer the case and has been corrected.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |